|
Royalty Pharma Plc (RPRX) |
|
|
|
Royalty Pharma Plc's Total Debt to Equity
RPRX's quarterly Total Debt to Equity and Total Debt, Equity growth
Despite a net increase in borrowings by 0.07%, Royalty Pharma Plc managed to enhance Total Debt to Equity in the forth quarter 2023 to 0.61, falling below the company's typical Total Debt to Equity.
Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 8 other companies have achieved lower Total Debt to Equity than Royalty Pharma Plc in the IV Quarter 2023. While Total Debt to Equity total ranking has improved so far in the forth quarter 2023 to 339, from total ranking in the third quarter 2023 at 1600 .
Explain Debt to Equity Ratio?
What is the structure of RPRX´s Total Debt?
How valuable is the RPRX´s Equity?
Select the Comparisons :
|
|
Select the Ratio:
|
|
RPRX Total Debt to Equity |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity Change |
5.87 % |
-7.98 % |
-5.71 % |
-3.15 % |
-7.06 % |
Y / Y Total Debt Change |
-13.79 % |
-13.78 % |
0.28 % |
0.29 % |
0.29 % |
Total Debt to Equity MRQ |
0.61 |
0.64 |
0.73 |
0.73 |
0.75 |
RPRX's Total
Ranking |
# 339 |
# 1600 |
# 995 |
# 1844 |
# 264 |
Seq. Equity Change |
5.21 % |
-2.33 % |
-0.08 % |
3.11 % |
-8.55 % |
Seq. Total Debt Change |
0.07 % |
-13.97 % |
0.07 % |
0.07 % |
0.07 % |
Total Debt to Equity forth quarter 2023 Company Ranking |
Within: |
No. |
Major Pharmaceutical Preparations Industry |
# 9 |
Healthcare Sector |
# 31 |
Overall Market |
# 339 |
Total Debt to Equity Statistics |
High |
Average |
Low |
0.75 |
0.66 |
0.56 |
(Dec 31 2022) |
|
(Jun 30 2021) |
Cumulative Royalty Pharma Plc's Total Debt to Equity
RPRX's Total Debt to Equity for the trailling 12 Months
RPRX Total Debt to Equity |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity TTM Growth |
5.87 % |
-7.98 % |
-5.71 % |
-3.15 % |
-7.06 % |
Y / Y Total Debt TTM Growth |
-13.79 % |
-13.78 % |
0.28 % |
0.29 % |
0.29 % |
Total Debt to Equity TTM |
0.67 |
0.71 |
0.72 |
0.71 |
0.7 |
Total
Ranking TTM |
# 18
| # 1738
| # 1959
| # 102
| # 21
|
Seq. Equity TTM Growth |
5.21 % |
-2.33 % |
-0.08 % |
3.11 % |
-8.55 % |
Seq. Total Debt TTM Growth |
0.07 % |
-13.97 % |
0.07 % |
0.07 % |
0.07 % |
On the trailing twelve months basis Despite of the net new borrowings of 0.07% during the twelve months period ending in IV Quarter 2023 Royalty Pharma Plc has managed to decrease Total Debt to Equity in the IV Quarter 2023 to 0.67, above the RPRX's average Total Debt to Equity. Total Debt to Equity is the average cumulative value over the last four quarters.
Among companies in the Major Pharmaceutical Preparations industry 2, during the past 12 months, other companies have achieved lower Total Debt to Equity than Royalty Pharma Plc. While Total Debt to Equity total ranking has improved so far to 18, from total ranking in previous 12 month period at 1738.
Explain Debt to Equity Ratio?
What is the structure of RPRX´s Total Debt?
How valuable is the RPRX´s Equity?
TTM Total Debt to Equity Company Ranking |
Within: |
No. |
Within the Major Pharmaceutical Preparations Industry |
# 3 |
Healthcare Sector |
# 5 |
Within the Market |
# 18 |
trailing twelve months Total Debt to Equity Statistics |
High |
Average |
Low |
0.72 |
0.65 |
0.58 | (Jun 30 2023) |
|
(Jun 30 2021) |
Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry | Total Debt to Equity | Dec 31 2023 MRQ Total Debt | Dec 31 2023 MRQ Equity | Eyenovia inc | 1.59 | $ 14.287 Millions | $ 8.999 Millions | Jazz Pharmaceuticals Plc | 1.53 | $ 5,712.942 Millions | $ 3,736.997 Millions | G1 Therapeutics Inc | 1.46 | $ 51.557 Millions | $ 35.386 Millions | Xoma Corporation | 1.40 | $ 124.061 Millions | $ 88.721 Millions | Alimera Sciences Inc | 1.40 | $ 64.489 Millions | $ 46.170 Millions | Biovie Inc | 1.36 | $ 10.195 Millions | $ 7.491 Millions | Catalent Inc | 1.36 | $ 5,005.000 Millions | $ 3,687.000 Millions | Bristol myers Squibb Company | 1.35 | $ 39,772.000 Millions | $ 29,485.000 Millions | Emergent Biosolutions Inc | 1.32 | $ 860.200 Millions | $ 649.300 Millions | Zoetis Inc | 1.32 | $ 6,567.000 Millions | $ 4,991.000 Millions | Soligenix inc | 1.29 | $ 3.261 Millions | $ 2.522 Millions | Summit Therapeutics Inc | 1.29 | $ 100.000 Millions | $ 77.692 Millions | Clene Inc | 1.23 | $ 16.521 Millions | $ 13.390 Millions | Lexicon Pharmaceuticals Inc | 1.07 | $ 99.508 Millions | $ 93.110 Millions | Merck and Co Inc | 0.93 | $ 35,055.000 Millions | $ 37,635.000 Millions | Elanco Animal Health Inc | 0.93 | $ 5,774.000 Millions | $ 6,223.000 Millions | Viatris Inc | 0.89 | $ 18,131.500 Millions | $ 20,467.400 Millions | Perrigo Company Plc | 0.85 | $ 4,073.400 Millions | $ 4,767.900 Millions | Ocular Therapeutix Inc | 0.82 | $ 74.925 Millions | $ 91.131 Millions | Biofrontera Inc | 0.81 | $ 3.904 Millions | $ 4.793 Millions | Pfizer Inc | 0.81 | $ 71,888.000 Millions | $ 89,288.000 Millions | Cryoport inc | 0.78 | $ 380.037 Millions | $ 489.023 Millions | Prestige Consumer Healthcare Inc | 0.75 | $ 1,199.340 Millions | $ 1,600.577 Millions | Lucy Scientific Discovery Inc | 0.75 | $ 0.060 Millions | $ 0.081 Millions | Vaxxinity Inc | 0.74 | $ 9.933 Millions | $ 13.409 Millions | Verastem inc | 0.70 | $ 40.086 Millions | $ 57.374 Millions | Mersana Therapeutics Inc | 0.68 | $ 25.231 Millions | $ 36.904 Millions | Ani Pharmaceuticals Inc | 0.66 | $ 285.669 Millions | $ 432.749 Millions | Royalty Pharma Plc | 0.61 | $ 6,135.285 Millions | $ 10,084.289 Millions | Aytu Biopharma Inc | 0.49 | $ 16.043 Millions | $ 32.853 Millions |
|